Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVERY trial (COVID-19 therapies)
2020-001113-21Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Mar 2020
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of hydrocortisone, tocilizumab, methylprednisolone, immune globulin, casirivimab and 3 more in coronavirus disease 2019 (COVID-19) and viral pneumonia (8 arms), sponsored by University of Oxford. Primary endpoint: All-cause mortality within 28 days of randomisation. Status: unknown.
02
Drugs
hydrocortisonetocilizumabmethylprednisoloneimmune globulincasirivimab
03
Conditions
coronavirus disease 2019 (COVID-19)viral pneumonia
Beyond the preview
Go deeper on 2020-001113-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001113-21.